Try Alerts Free   |   Login
Health Care › Services-Medical Laboratories

OPGN Price Correlated With Financials For OpGen

Free historical financial statements for OpGen Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 29 quarters since 2015. Compare with OPGN stock chart to see long term trends.

OPGN Stock Compared to Quarterly

OPGN Income Statement

Revenue, Net:469745
Revenue Per Share:0.0101
Cost of Goods & Services Sold:291997
Selling, General & Admin Expense:2625053
Research & Development Expense:2316441
Total Operating Expenses:6315485
Operating Income:-6803716
Net Income:-6803716
Earnings Per Share, Basic:-0.15
Shares Outstanding, Basic Avg:46558250

OPGN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:514269
Change in Accounts Receiveable:-889810
Net Cash from Operations:-5041400
Net Cash from Operations Per Share:-0.1083
Net Cash from Financing Activities:-17529
Property, Plant & Equipment Purchases:38713
Net Cash from Investing Activities:-38713
Net Change in Cash & Equivalents:-5510735

OPGN Balance Sheet

Cash and Cash Equivalents:31121451
Accounts Receivable, Net:265885
Inventories:4810029
Total Current Assets:33492711
Property, Plant & Equipment, Net:3721720
Total Assets:64259433
Accounts Payable:865440
Current Portion of Long-Term Debt:14394824
Total Short-Term Liabilities:19012875
Total Liabilities:30088299
COMPANY PROFILE
Note 1 - Organization
OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. On April 1, 2020, OpGen completed its business combination transaction (the “Transaction”) with Curetis N.V., a public company with limited liability under the laws of the Netherlands (the “Seller” or “Curetis N.V.”), as contemplated by the Implementation Agreement, dated as of September 4, 2019 (the “Implementation Agreement”), by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly-owned subsidiary of the Company (the “Purchaser”). Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”), and certain other assets and liabilities of the Seller (together, “Curetis”) (see Note 4). References to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters are in Rockville, Maryland and the Company’s principal operations are in Rockville, Maryland; Holzgerlingen and Bodelshausen, Germany; and Vienna, Austria. The Company operates in one business segment.
OpGen Overview
OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Our current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
Following its initial announcement in October 2020, the Company discontinued its QuickFISH and PNA FISH product portfolio in its entirety during the first quarter of 2021 (see Note 12). The Company's FISH customers and distribution partners have been informed accordingly and last orders were received and processed in the first quarter of 2021. The discontinuance of these product lines did not qualify for discontinued operations reporting.
The focus of OpGen is on its combined broad portfolio of products, which include high impact rapid diagnostics and bioinformatics to interpret Antimicrobial resistance (AMR) genetic data. OpGen will continue to develop and seek FDA and other regulatory clearances or approvals, as applicable, for the Unyvero UTI and IJI products. OpGen will continue to offer the FDA-cleared Unyvero LRT and LRT BAL Panels, Acuitas AMR Gene Panel diagnostic test, as well as the Unyvero UTI Panel as a RUO product to hospitals, public health departments, clinical laboratories, pharmaceutical companies and contract research organizations, or CROs. OpGen will also continue to commercialize its CE Marked Unyvero Panels in Europe and other global markets via distributors.

Data imported from OpGen Inc. SEC filings. Check original filings before making any investment decision.